MapLight Therapeutics, Inc. · NASDAQ:MPLT
MapLight Therapeutics — Investor Presentation (November 2026)
28 slides from MapLight Therapeutics's investor presentation, Nov 16, 2026
Slide 1: Corporate Presentation November 16, 2026
Corporate Presentation November 16, 2026
Slide 2: Forward-looking statements disclaimer
This presentation and any accompanying oral commentary have been prepared by MapLight Therapeutics, Inc. (“MapLight”, “we,” “us,” “our,” the “Company”, or similar terms) for informational purposes only and not for any other purpose. This presentation contains trademarks, service marks, trade names a
Slide 3: MapLight Therapeutics: Improving Lives of Patients With CNS Disorders
3 MapLight Therapeutics Working to Improve the Lives of Patients Suffering From Debilitating CNS Disorders Novel M1/M4 muscarinic agonist in combination with a peripheral antagonist with a lead indication in schizophrenia, a disease affecting >20 million people globally (1) ~20-35%+ of patients with
Slide 4: Broad and Diversified Pipeline
Program Circuit Indications Preclinical Phase 1 Phase 2 Phase 3 Anticipated Milestones ML-007C-MA M1/M4 agonist co-formulated with PAC Direct and Indirect Pathways Schizophrenia Engage with FDA at EOP2 meeting Alzheimer’s Disease Psychosis Topline results in 2H 2027 ML-004 5-HT1B/1D agonist Dorsal R
Slide 5: ML-007C-MA Lead Asset for Schizophrenia and ADP
ML-007C-MA Lead Asset in Development for Schizophrenia and ADP
Slide 6: Unmet Need in Schizophrenia Remains After First Muscarinic Approval
Existing evidence is derived from post hoc or exploratory pooled analyses across two studies Cognitive benefit remains unproven ~30% show no meaningful response to treatment (1) ~40-50% experience an inadequate response to standard of care (1) ~70% discontinue oral therapies within 18 months, often
Slide 7: ZEPHYR Phase 2 results summary
Met the primary endpoint on PANSS Total Score (ES=0.37), with a stronger effect in completers in which there are no modelled assumptions of missing data (ES=0.50) Achieved significance on CGI-S and PANSS Positive Marder Factor Statistically Significant Across Complementary Measures Prespecified Cogn
Slide 8: Primary Endpoint: PANSS Total Score
LS Mean CFB (SE) in PANSS Total Score Primary Endpoint: PANSS Total Score 210/3 mg BID Met Primary Endpoint Change From Baseline in PANSS Total Score (LS Mean Difference) *p<0.05 LS = least squares; SE = standard error. Note: Negative treatment deltas favor active treatment; effect size presented as
Slide 9: PANSS Total Score Completer Analysis
Week 1 Week 2 Week 3 Week 4 Week 5 Primary Endpoint: PANSS Total Score Robust Effect Demonstrated in Prespecified Completer Analysis Change From Baseline in PANSS Total Score (LS Mean Difference) LS Mean CFB (SE) in PANSS Total Score *p<0.05, **p<0.01 MMRM= Mixed model for repeated measures. Note: N
Slide 10: Key Secondary Endpoint: CGI-S
Key Secondary Endpoint: CGI-S Significant Improvement Corroborates PANSS Improvement Change From Baseline in CGI-S (LS Mean Difference) LS Mean CFB (SE) in CGI-S Clinically meaningful and statistically significant improvement in CGI-S vs. placebo at Week 5 0.38-point improvement -0.75 active vs. -0.
Slide 11: PANSS Positive Symptoms
Change From Baseline in PANSS Positive Symptoms (LS Mean Difference) *p<0.05 , **p<0.01 Note: Negative treatment deltas favor active treatment; effect size presented as an absolute value. Analysis based on the mITT population. PANSS Positive Symptoms Significant Improvement in PANSS Positive Marder
Slide 12: Pre-specified Cognitive Composite Score Results
Pre-specified Cognitive Composite Score Results Cognitive Composite Score CFB to Week 5 PANSS Total Score CFB to Week 5 Cognitive Composite Score Placebo 210/3 mg BID N with baseline impairment N=37 N=31 LS Mean Change from Baseline 0.11 0.55 LS Mean Difference vs. Placebo 0.44 P-value p=0.041 Effec
Slide 13: Implications of Cognitive Signal Beyond ZEPHYR
Implications of Cognitive Signal Beyond ZEPHYR Supports Rationale for VISTA and Broader Development 13 Cognitive impairment is estimated to affect >80% of patients with schizophrenia (1) Cognitive impairment is a major determinant of long-term functional outcomes, including employment, independent l
Slide 14: 210/3 mg BID Effect Across Multiple Endpoints
210/3 mg BID Demonstrated Effect Across Multiple Endpoints and Symptom Domains 14 N Active / PBO LS Mean Difference [95% CI] Effect Size P-value PANSS Total Score – mITT 93 / 103 0.37 0.015 PANSS Total Score - Completers 73 / 88 0.50 0.002 CGI-S 93 / 103 0.48 0.002 Cognitive Composite 31 / 37 0.51 0
Slide 15: ML-007C-MA Was Generally Well Tolerated
ML-007C-MA Was Generally Well Tolerated 15 Single serious adverse event occurred in placebo arm was worsening schizophrenia. Adverse events, primarily cholinergic in nature, were mostly mild No serious or drug-related severe TEAEs occurred with either dose (1) The only severe TEAE (pneumonia) was as
Slide 16: Rates of TEAEs With BID Dosing
16 Placebo N=104 210/3 mg BID N = 99 Mild Moderate Mild Moderate Nausea 6% 0 20% 9% Vomiting 1% 2% 9% 4% Dyspepsia (3) 0 1% 8% 1% Constipation 3% 0 8% 1% Abdominal pain (3) 3% 0 6% 3% Diarrhea 1% 0 5% 0 GERD 2% 0 2% 0 Rates of TEAEs With BID Dosing GI TEAEs ≥2% in Active Arm and > Placebo Most Adver
Slide 17: Rates of TEAEs for Cobenfy in Pivotal Studies
EMERGENT-2 EMERGENT-3 Placebo Active Placebo Active Discontinuations Due to TEAE 5.6% (2) 7.1% (2) 5.5% (3) 6.4% (3) Due to GI TEAE Not reported 3.2% (4) Not reported 3.2% (4) Utilization of Lower Dose Dose Reduction Due to TEAE(1) 0 5.6% 0.8% 0.8% Inability to Reach Target Dose 1.6% (2) 17.5% (2) 9
Slide 18: Effect Size Within Range of Approved Antipsychotics
18 PANSS Total Score PANSS Positive Symptoms Score Sources: Approved antipsychotic effect sizes per Huhn et al., Lancet 2019; Correll et al., JAMA Psychiatry 2020; Cobenfy per Fabiano et al., 2025 meta-analysis. Note: Standardized Effect Sizes (Cohen’s d) shown. Assessments reflect management’s curr
Slide 19: ML-007C-MA Target Product Profile Differentiation
Program Mechanism of Action Efficacy in RCTs 210/3 mg BID hit primary endpoint Cognitive Improvement Prespecified secondary endpoint Tolerability/Safety Meaningfully lower rates of significant side effects No Fasting Requirement Taken with food Simple Titration One-dose titration Dosing Frequency QD
Slide 20: Phase 3 Program and Path to NDA Submission
Phase 3 Program and Path to NDA Submission Confirmatory Pivotal Trial Expected to Support Initial Approval Trial in ADP patients evaluating 210/3 mg BID (potentially registrational) Enrollment ongoing, supported by ZEPHYR's prespecified cognitive signal Ongoing VISTA (Study 221) Topline results expe
Slide 21: ML-007 Target Positioning
ML-007 Target Positioning: Clinically Meaningful Symptom Improvement, Well Tolerated, Built for Simple, Real-World Dosing Consistent, clinically meaningful benefit across PANSS, global measures, and responder analyses Effect size of 0.37 in mITT and 0.50 among study completers Prespecified cognitive
Slide 22: ML-004 5-HT1B/1D Agonist for Autism Spectrum Disorder
ML-004 5-HT1B/1D Agonist in Development for Autism Spectrum Disorder (ASD)
Slide 23: Unmet Need in ASD Irritability Remains High
Unmet Need in ASD Irritability Remains High ~830K adolescents diagnosed with ASD (U.S., 2039E) (1) ~20-35%+ experience clinically significant irritability or aggression (2) 1 in 6 young people with ASD receive antipsychotics (3) Only 2 approved therapies both with warnings and precautions relevant t
Slide 24: ML-004 Irritability Outcomes
24 Irritability Outcomes Includes Subjects with ABC-I >16 at Baseline ABC-I Subscale (1) Care partner-reported CGI-I Irritability Domain (2) Clinician-reported Two measures of irritability assessed by different raters LS Mean Difference vs. Placebo (95% CI), by Scale and Age Group Total N = 26 Adole
Slide 25: ML-004 Potential to Address Unmet Needs
ML-004 Has the Potential to Address Unmet Needs Through Established Development Path ML-004 demonstrated clinically meaningful improvements in irritability in adolescents with moderate or greater baseline irritability across both caregiver- and clinician-rated scales ABC-I (effect size of 1.33, nomi
Slide 26: Appendix
—e& MapLight ppendix
Slide 27: ZEPHYR Study Outline
Screening Period (Day -7 to -1) Blinded Treatment Period (Day 1 to 35) Follow-up Period (Day 36 to 42) Week 1 Week 2 Week 3 Week 4 Week 5 N = 307 Randomized 1:1:1 Sites: 25 (US only) Placebo (N=104) ML-007C-MA 330/6 mg QD (1) (N=102) ML-007C-MA 210/3 mg BID (1) (N=101) Primary Endpoint Stu
Slide 28: VISTA Study Outline
28 Screening Period (Day -35 to -1) Blinded Treatment Period (Day 1 to 49) Follow-up Period (7 + 2 days after last dose) Week 1 Week 2 Week 3 Week 5 Week 7 ML-007C-MA 210/3mg BID (n=150) Primary Endpoint Week 1 105/1.5mg BID Weeks 2-7 210/3mg BID (1) Placebo BID (n=150) N = 300 Randomized 1:1 Sites:
MapLight Therapeutics — Investor Presentation (November 2026) on 6ix